Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price was down 1.6% during mid-day trading on Tuesday . The stock traded as low as $26.47 and last traded at $26.6110. Approximately 36,266,027 shares changed hands during mid-day trading, a decline of 15% from the average session volume of 42,457,094 shares. The stock had previously closed at $27.05.
Trending Headlines about Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer’s second-quarter update was encouraging: non-COVID products grew 5%, the company raised its 2026 guidance, and management reiterated a target of approximately $9.7 billion in cost savings. The results suggest Pfizer’s broader portfolio is beginning to offset pandemic-related revenue declines. Pfizer Q2 2026 Earnings Call Transcript
- Positive Sentiment: Analysts highlighted Pfizer’s second-quarter earnings beat and raised 2026 revenue outlook as evidence that the company may be turning a corner, although the post-COVID transition remains challenging. Pfizer Rises Almost 7% Post Q2 Results
- Positive Sentiment: The stock’s sizable dividend yield remains a key attraction for income investors, particularly compared with the S&P 500’s average yield. Pfizer vs AbbVie: What’s the Better Dividend Stock for Investors in 2026?
- Neutral Sentiment: Pfizer extended its advance for a seventh consecutive session, indicating improved investor sentiment following its quarterly results, though the extended rally may also leave the shares vulnerable to profit-taking. Pfizer Extends Rally to Seventh Straight Session
- Neutral Sentiment: Pfizer and BioNTech received European authorization for an updated COVID-19 vaccine, but the companies are pursuing different post-pandemic strategies; Pfizer is emphasizing scale and cost reductions while broadening its non-COVID pipeline. Pfizer vs BioNTech: Which Pharma Giant Is Better Positioned for the Post-COVID Era?
- Negative Sentiment: Investors remain concerned that Pfizer’s earnings have fallen sharply this year and that its roughly 6.4% dividend yield could become difficult to maintain, raising the risk of a future dividend reduction. Pfizer’s Earnings Have Declined 58% This Year
- Negative Sentiment: Declining COVID product sales and upcoming patent losses continue to cloud Pfizer’s long-term growth outlook, potentially limiting the benefit of cost cuts and pipeline expansion. Is Pfizer Turning a Corner as Its Non-COVID Pipeline Widens?
Analysts Set New Price Targets
A number of brokerages recently issued reports on PFE. Weiss Ratings reiterated a “hold (c)” rating on shares of Pfizer in a report on Monday, August 3rd. JPMorgan Chase & Co. dropped their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 8th. Citigroup lifted their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. BMO Capital Markets lowered their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Finally, Bank of America cut their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $28.28.
Pfizer Price Performance
The firm has a market capitalization of $151.67 billion, a PE ratio of 35.01 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock has a fifty day moving average price of $25.05 and a 200-day moving average price of $26.18.
Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the company earned $0.78 earnings per share. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.97 EPS for the current fiscal year.
Pfizer Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.5%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 226.32%.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Godfrey Financial Associates Inc. purchased a new stake in shares of Pfizer during the fourth quarter worth about $26,000. Keb Asset Management LLC acquired a new stake in Pfizer in the 2nd quarter worth approximately $26,000. HFM Investment Advisors LLC grew its position in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the last quarter. Evolution Wealth Management Inc. increased its stake in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. Finally, Abound Financial LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $31,000. 68.36% of the stock is owned by institutional investors and hedge funds.
About Pfizer
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Read More
- Five stocks we like better than Pfizer
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
